Author

Teresa Kaserer

Universität InnsbruckORCID 0000-0003-0372-1885Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Molecular Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:protein sequence· 1 Approach:statistical model· 1

Frequent Co-Authors

Albert SnowballiD· 1 shared Alexandre MouravleviD· 1 shared Andreas FeichtneriD· 1 shared Andreas LiebiD· 1 shared Andreas NaschbergeriD· 1 shared Angela J. WuiD· 1 shared Anna Fürst· 1 shared Anna SauerweiniD· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Albert SnowballORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular Biologynpj VirusesPeer-reviewedJun 24, 2024

Identification of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir

Laura Krismer, Helge Schöppe, Stefanie Rauch…·Emmanuel Heilmann

The paper evaluates the effectiveness of SARS-CoV-2 protease inhibitors against MERS-CoV proteases and identifies resistance mechanisms.

22 citationstop 2%

experimental assay

𝕏 PostBluesky

BioinformaticsbioRxivPreprintJan 18, 2022

Resistor: an algorithm for predicting resistance mutations using Pareto optimization over multistate protein design and mutational signatures

Nathan Guerin, Andreas Feichtner, Eduard Stefan…·Bruce Randall Donald

RO_SCPLOWESISTORC_SCPLOW predicts resistance mutations by optimizing four criteria using Pareto frontiers, identifying clinically relevant mutations in EGFR and BRAF inhibitors.

1 citation

humanprotein sequence

𝕏 PostBluesky

NeuroscienceScience AdvancesPeer-reviewedApr 5, 2019

Olanzapine: a full and potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics

Mikail Weston, Teresa Kaserer, Angela J. Wu…·Andreas Lieb

The paper identifies olanzapine as a potent and full agonist for the hM4D(Gi) DREADD, enabling clinical translation of chemogenetics for CNS diseases.

61 citationstop 4%

humanexperimental assay

𝕏 PostBluesky